Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
toripalimab + etoposide + cisplatin + carboplatin
- Development stage
- Unknown
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Toripalimab is a humanized IgG4 monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor. By blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, it restores the ability of T-cells to recognize and attack tumor cells. In the specific clinical context of genitourinary small cell carcinoma (GUSCC), toripalimab is being investigated as a first-line treatment in combination with etoposide and platinum-based chemotherapy (either cisplatin or carboplatin), a regimen often referred to as EP/EC. This combination therapy aims to leverage the cytotoxic effects of chemotherapy alongside immune checkpoint inhibition to treat locally advanced or metastatic forms of this rare and aggressive malignancy. The development of this specific regimen is currently being led by Sun Yat-sen University Cancer Center through a Phase II multicenter trial.
- Brand names
- LOQTORZITUOYI
- Other names
- Toripalimab Plus EP/ECToripalimab Plus Etoposide and Platinum-based Chemotherapy
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)DNA
Beyond the preview
Go deeper on toripalimab + etoposide + cisplatin + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on toripalimab + etoposide + cisplatin + carboplatin.